|
| Company name | Pfizer, Inc. | | Company type | Public | | Industry | Pharmaceutical | | Founded | 1849 | | Headquarters | New York City, New York, U.S. | | Area served | Worldwide | | Key people | Ian Read (President & CEO) | | Products | List of Pfizer products | | Revenue | (+) US$ 67.809 billion (2010) | | Operating income | (-) US$ 9.422 billion (2010) | | Net income | (-) US$ 8.257 billion (2010) | | Total assets | (-) US$ 195.014 billion (2010) | | Total equity | (-) US$ 88.265 billion (2010) | | Employees | 110,600 (2010) | | Subsidiary | Agouron Pharmaceuticals, G. D. Searle & Company, Greenstone, Parke-Davis, Pharmacia, Upjohn, Warner Lambert, Wyeth |
|
|
Pfizer, Inc. ( ) (-enˈfaɪzər) is an American multinational pharmaceutical corporation. The company is based in New York City, New York with its research headquarters in Groton, Connecticut, United States. Pfizer produces Lipitor (atorvastatin, used to lower blood cholesterol); the neuropathic pain/fibromyalgia drug Lyrica (pregabalin); the oral antifungal medication Diflucan (fluconazole), the antibiotic Zithromax (azithromycin), Viagra (sildenafil) for erectile dysfunction, and the anti-inflammatory Celebrex (celecoxib) (also known as Celebra in some countries outside the USA and Canada, mainly in South America). Its headquarters are in Midtown Manhattan, New York City.
Pfizer's shares were made a component of the Dow Jones Industrial Average on April 8, 2004.
Pfizer pleaded guilty in 2009 to the largest health care fraud in U.S. history and received the largest criminal penalty ever levied for illegal marketing of four of its drugs. Called a repeat offender, this was Pfizer's fourth such settlement with the U.S. Department of Justice in the previous ten years.
On January 26, 2009, Pfizer agreed to buy pharmaceutical giant Wyeth for US$68 billion, a deal financed with cash, shares and loans. The deal was completed on October 15, 2009.
|
|
|
RSS
